Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

1. www.astrazeneca.com › media-centre › press-releasesAstraZeneca aims to redefine breast cancer care with new data...

   www.astrazeneca.com › media-centre › press-releases

   • Αποθηκευμένο αντίγραφο

   22 Νοε 2022 · With Enhertu (trastuzumab deruxtecan), a HER2-directed ADC, AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.

   • Enhertu demonstrated a median progression-free survival ... - AstraZeneca

     With Enhertu (trastuzumab deruxtecan), a HER2-directed...

2. www.astrazeneca.com › media-centre › press-releasesEnhertu demonstrated a median progression-free survival ... -...

   www.astrazeneca.com › media-centre › press-releases

   • Αποθηκευμένο αντίγραφο

   2 Ιουν 2024 · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.

3. Κυριότερες Ειδήσεις

   • precisionmedicineonline

     AstraZeneca Advancing Plan to Launch Biomarker-Driven Drugs as Alternative to Chemo in Breast Cancer

     The drugmaker wants to establish Enhertu in HER2-ultralow breast cancer and even HER2-negative tumors but remains committed to precision medicine strategies.

     2 εβδομάδες Πριν από

   • BBC on MSN.com

     Breast cancer patients denied life-extending drug in cost row

     More than a thousand patients with advanced breast cancer are being denied a drug that can keep them alive for longer. It is already available in 19 countries in Europe - including in Scotland - but not in the rest of the UK.

     6 ημέρες Πριν από

   • 

     Zenopa

     Roche’s New Breast Cancer Drug Itovebi: FDA Approval and Market Impact

     2 εβδομάδες Πριν από

   • FiercePharma

     Roche burnishes breast cancer portfolio with FDA approval for Itovebi, a threat to Novartis and AZ

     2 εβδομάδες Πριν από

   • manufacturingdigital

     How Manufacturing is Aiding the Fight Against Breast Cancer

     From manufacturing vital drugs to driving research to raising funds and awareness, leaders like AstraZeneca, Ford and Estée Lauder are having an impact

     6 ημέρες Πριν από

4. www.astrazeneca.com › our-therapy-areas › oncologyBreast Cancer - AstraZeneca

   www.astrazeneca.com › our-therapy-areas › oncology

   • Αποθηκευμένο αντίγραφο

   With more than 35 ongoing breast cancer trials with our approved and potential new medicines, we are focused on the needs of people living with breast cancer now and in the future.

5. www.fda.gov › fda-approves-capivasertib-fulvestrant-breast-cancerFDA approves capivasertib with fulvestrant for breast cancer

   www.fda.gov › fda-approves-capivasertib-fulvestrant-breast-cancer

   • Αποθηκευμένο αντίγραφο

   16 Νοε 2023 · On November 16, 2023, the Food and Drug Administration approved capivasertib (Truqap, AstraZeneca Pharmaceuticals) with fulvestrant for adult patients with hormone receptor (HR)-positive, human...

6. www.ft.com › content › 9a9a3650-4e5b-4dcb-aeb7-1aa8533fd6d5AstraZeneca-Daiichi drug sharply raises breast cancer survival...

   www.ft.com › content › 9a9a3650-4e5b-4dcb-aeb7-1aa8533fd6d5

   5 Ιουν 2022 · Oncologists are hopeful a drug developed by AstraZeneca and Daiichi Sankyo will change how doctors treat the most common type of late-stage breast cancer, after data showed it doubled the...

7. www.reuters.com › business › healthcare-pharmaceuticalsAstraZeneca boosts oncology credentials with breast cancer trial...

   www.reuters.com › business › healthcare-pharmaceuticals

   21 Φεβ 2022 · AstraZeneca said its Enhertu cancer drug has been shown to significantly help women suffering from a type of breast cancer that leaves them with poor treatment options, opening the door to a...

8. www.ft.com › content › 37edd17b-145c-42ef-a725-c16c4f8861b0A pharma partnership that brought a breakthrough in breast cancer

   www.ft.com › content › 37edd17b-145c-42ef-a725-c16c4f8861b0

   6 Ιαν 2023 · When Daiichi Sankyo and AstraZeneca announced impressive results for their breast cancer treatment Enhertu, oncologists took to their feet to applaud. “It was a goosebump moment, sending...